43 results
8-K
COGT
Cogent Biosciences Inc
17 Jan 20
Termination of a Material Definitive Agreement
4:50pm
-escalation ofATTCK-17-01 was based on a deprioritization of a target approach relative to the emerging clinical competitive environment in relapsed
DEFA14A
COGT
Cogent Biosciences Inc
30 Apr 19
Additional proxy soliciting materials
5:27pm
as instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also help the environment
8-K
EX-99.1
COGT
Cogent Biosciences Inc
7 Jan 19
Regulation FD Disclosure
8:02am
functionality in the solid tumor environment Expanding the universe of T cell therapy targets universal antibody-targeted T cells for hematologic and solid
10-K
thkn22r3zr9xbh
28 Mar 19
Annual report
7:31am
S-3
its3tw0z1qet5
2 Apr 19
Shelf registration
12:00am
10-Q
q1q7pabvu3jvr91pck
14 May 18
Quarterly report
7:01am
DEF 14A
wjhjvaew
30 Apr 19
Definitive proxy
5:25pm
8-K
EX-10.1
ot8u364dp
9 Jul 21
Entry into a Material Definitive Agreement
4:01pm
424B5
5hcp gi1zp
2 Dec 20
Prospectus supplement for primary offering
5:06pm
S-3
EX-1.2
zsyr1tdotpeep7j3
2 Apr 19
Shelf registration
12:00am